Psilocybin and Inflammatory and Mitochondrial Stress Markers in Parkinson Disease: A Nonrandomized Clinical Trial
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: This nonrandomized clinical trial assesses associations between psilocybin therapy and changes in systemic markers of inflammation and mitochondrial stress in people with Parkinson disease and mood dysfunction.
Source: JAMA Psychiatry
Authors: Ellen R. Bradley, Parker Kelley, Balázs Szigeti, Kristen Nishimi, Martin Picard, Kimberly Sakai, Gisele Fernandes-Osterhold, Jill L. Ostrem, Caroline M. Tanner, Connie Ludwig, Katiah Llerena, Patrick R. Finley, Zachary Busby, Amber McKernan, Madeline Marie Pantoni, Andrew D. Penn, Aliss C. C. Wang, Jose Rafael Pantoja Zuzuarregui, Joshua D. Woolley, Aoife O’Donovan
Language: English
Subfield: Clinical Psychology
Field: Psychology
Domain: Social Sciences
Open Access status: green
OpenAlex ID: W7223091331
